↓ Skip to main content

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Overview of attention for article published in Clinical Cancer Research, October 2015
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Published in
Clinical Cancer Research, October 2015
DOI 10.1158/1078-0432.ccr-15-1221
Pubmed ID
Authors

Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni R. Abdul Razak, Katherine Van Loon, Amita Patnaik, Philippe L. Bedard, Ariceli A. Alfaro, Muralidhar Beeram, Lieve Adriaens, Carrie M. Brownstein, Israel Lowy, Ana Kostic, Pamela A. Trail, Bo Gao, A. Thomas DiCioccio, Lillian L. Siu

Abstract

Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Ang2 with high affinity, but shows no binding to Ang1. The main objectives of this trial were to determine the safety, tolerability, dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of nesvacumab. Nesvacumab was administered intravenously every two weeks (Q2W) with dose escalations from 1 to 20 mg/kg in patients with advanced solid tumors. A total of 47 patients were treated with nesvacumab. No patients in the dose escalation phase experienced DLTs, therefore a maximum tolerated dose (MTD) was not reached. The most common nesvacumab-related adverse events were fatigue (23.4%), peripheral edema (21.3%), decreased appetite and diarrhea (each 10.6%) (all grade ≤ 2). Nesvacumab was characterized by linear kinetics and had a terminal half-life of 6.35 to 9.66 days in a dose-independent manner. Best response by RECIST 1.1 in 43 evaluable patients included 1 partial response (adrenocortical carcinoma) of 24 weeks duration. Two patients with hepatocellular carcinoma had stable disease (SD) > 16 weeks, with tumor regression and >50% decrease in alpha-fetoprotein. Analyses of putative angiogenesis biomarkers in serum and tumor biopsies were uninformative for treatment duration. Nesvacumab safety profile was acceptable at all dose levels tested. Preliminary antitumor activity was observed in patients with treatment-refractory advanced solid tumors. Based on cumulative safety, antitumor activity, PK and PD data, the 20 mg/kg dose was determined to be the RP2D.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 4%
Unknown 23 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 21%
Researcher 5 21%
Unspecified 3 13%
Other 3 13%
Student > Postgraduate 2 8%
Other 5 21%
Unknown 1 4%
Readers by discipline Count As %
Medicine and Dentistry 9 38%
Agricultural and Biological Sciences 5 21%
Biochemistry, Genetics and Molecular Biology 4 17%
Unspecified 4 17%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Other 0 0%
Unknown 1 4%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2016.
All research outputs
#9,918,739
of 12,389,742 outputs
Outputs from Clinical Cancer Research
#8,076
of 9,082 outputs
Outputs of similar age
#184,214
of 267,620 outputs
Outputs of similar age from Clinical Cancer Research
#134
of 154 outputs
Altmetric has tracked 12,389,742 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 9,082 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,620 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 154 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.